메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

All Approved Indications of Five Akeso's Innovative Drugs Inc…

HONG KONG, Dec. 7, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as well as those participating in national reimbursement negotiations for the first time. With these inclusions, all approved indications for Akeso's five
- 김갑성 기자
- 2025-12-07 14:18
Innovent Announces Inclusion of Seven Innovative Drugs in…

[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (te
- 김갑성 기자
- 2025-12-07 11:40
Leaders Dental Leads Korea's Prosthodontic Market With L…

SEOUL, South Korea, Dec. 7, 2025 -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructure enables high-volume prosthetics manufacturing and exceptional capability in handling complex clinical cases. By combining state-of-the-art digital equipment with highly skilled dental technicians, the company's clinically integrated collaboration model maximizes both accuracy and efficiency in prosthetic produc
- 김갑성 기자
- 2025-12-07 08:00
Vivacta Bio Announces Promising First-in-Human Results for G…

SHANGHAI, Dec. 6, 2025 -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The presentation, titled "Precision In Vivo CAR-T Generation via CLAMP-
- 김갑성 기자
- 2025-12-06 22:45
Seegene Establishes French Subsidiary to Expand Europe…

- France becomes Seegene's ninth overseas sales subsidiary and third in Europe, following Italy and Germany - The country ranks as Europe's second-largest molecular diagnostics market, driven by demand in sexually transmitted infections and gastrointestinal testing, and respiratory virus detection. - The new subsidiary is expected to accelerate broader adoption of Seegene's developing solutions, CURECA™ and STAgora™, in Europe SEOUL, South Korea, Dec. 5, 2025 -- Seegene, Inc., a global leader in molecular diagnostics (MDx), announced today the establishment of a n
- 김갑성 기자
- 2025-12-05 22:00
Neurophet Participates RSNA 2025, Showcased Real-World Clin…

Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session SEOUL, South Korea, Dec. 5, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) a
- 김갑성 기자
- 2025-12-05 22:00
Prof. Gang Shen's Research Paper about Mandibular Advan…

SHANGHAI, Dec. 5, 2025 -- A clinical study developed by Professor Gang Shen's Orthodontic Team from Taikang Bybo Dental has been officially published in the Journal of Aligner Orthodontics (JAO). The article presents key findings on the use of Mandibular Advancement Repositioning Therapy (MART) implemented through the S8-SGTB, a clear orthodontic appliance jointly developed by Smartee Denti-Technology and Prof. Gang Shen's team. The insight of the report expands non-surgical treatment possibilities for adult patients with skeletal Class II malocclusion. Titled "Working Mec
- 김갑성 기자
- 2025-12-05 18:00
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urg…

- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts gathered to address platinum resistance in advanced ovarian cancer with Antibody Drug Conjugates (ADCs). The discussion underscored the pressing need to rethink traditional definitions of platinum resistance and explore new strategies to treat one of the most persistent and challenging treatment obsta
- 김갑성 기자
- 2025-12-05 16:00
Post-Disaster Support | Emergency Financial Assistance for…

HONG KONG, Dec. 5, 2025 -- The Level 5 fire at Wang Fuk House, Tai Po, on 26 November has left nearly 2,000 households homeless and plunged many families into hardship. Recovery and rebuilding after a disaster is a long journey that requires support from all sectors of society. To this end, the registered Hong Kong charity "Cancer Information.com.hk Charity Foundation" (Inland Revenue Department tax-exempt ref. no.: 91/15162), with generous funding from the Li Ka Shing Foundation, is launching an emergency drug subsidy programme specifically for cancer patients or survivors a
- 김갑성 기자
- 2025-12-05 14:03
TransThera Publishes Clinical Studies of Tinengotinib (TT…

NANJING, China and GAITHERSBURG, Md., Dec. 5, 2025 -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (Impact Factor: 38.6). Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, frequently driven by FGFR2 fusions-genomic alterations that are targetable by FGFR inhibitors such as pemigatinib and futibatinib. However, resistance to these agents commonly arises due to secondary FGFR2
- 김갑성 기자
- 2025-12-05 12:31

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 18시 20분